




STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, July 18, 2013
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 128



MINUTES

Committee Members Present:

Kort Delost, R.Ph.

Lisa Hunt, R.Ph.

Roger Martenau, M.D.

Jameson Rice, Pharm.D.

Julia Ozbolt, M.D.

Elizabeth Young, Pharm.D.

Committee Members Excused:

Ellie Brownstein, M.D.

Bernadette Kiraly, M.D.

Beth Johnson, R.Ph.

Dept. of Health/Div. of Health Care Financing Staff Present:

Timothy Morley R.Ph.

Bobbi Hansen, CPhT

Robyn Seely, Pharm.D.

Trevor Smith, CPhT

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Juanita Lake, Pharm.D. MSc EBHC(Oxon)

Gary Oderda, Pharm.D., M.P.H

Bryan Larson, Pharm.D.

Other Individuals Present:

Kelsey Richards

Kari Murray, BI

Linda Craig, AZ

Raphael Wilson, BMS

Lori Harwarth, Bayer

Wayne Roberts, GSK

Nicole Kesty, AZ

Scott Larson, BMS

Lori Blackner, Pfizer

Meeting conducted by: Kort Delost

1. Review and Approval of May minutes: Julia Ozbolt moved to approve the minutes, Elizabeth Young seconded the motion. Motion approved unanimously.
2. Housekeeping: Lisa Hunt reported on a presentation to a legislative committee about the PDL. She said that August 1st will be the next PDL update. She mentioned that some states have a single state PDL. She also asked the committee if they had a version of a Roberts Rules of Order they would like to implement in P&T meetings.
3. Lisa Hunt asked for clarification for Xa inhibitors and GLP-1 drug classes. She said after the motions passed in the previous meeting, some board members felt there were still questions and the motions that passed were unclear. For this reason, she included summaries of the findings by the UofU DRRC on both the Xa and GLP-1 classes.

- Kort Delost clarified what the charge and duties of the P&T committee are, and said that the committee may try to do more than what they are responsible for.
- Elizabeth Young stated that there was some discussion in last meeting comparing the drugs that was confusing or not entirely correct. She says that all drugs presented in last meeting were all equally safe and effective, and no one agent stands out.
- Jameson Rice said that we should look at ease of dosing.
- Lisa Hunt said that if a patient is not able to take a formulation or requires a different type of medication in the class, the drug is still available through an authorization process. No drug in the class discussed would be eliminated or completely unavailable for a patient. She also mentioned the efficient PA process that Utah Medicaid employs to get medication to the patient. In addition, an online portal to simplify the process of obtaining a prior authorization for a patient is also available.
- Kort Delost clarified that the GLP-1 drugs discussed are second line agents, and would require some sort of prior therapy and documentation on the therapy in order to obtain. He questions the committee if it is worthwhile to revisit the classes.
- Jameson Rice says that he does not feel comfortable with the motions passed previously. Other members of the committee feel the same way, and wish to discuss the drug classes and make a decision.
- Lisa Hunt showed some of the PDL coverage for other states on drugs in both of the classes discussed.
- **Elizabeth Young made a motion to approve for use all GLP-1 as they are equally safe and effective. Lisa Hunt seconded the motion. All were in favor.**
- Clarification discussed on the Xa inhibitors included concerns expressed for rural patient accessibility issues.
- Lisa Hunt said that Utah Medicaid allows a 72 hour emergency supply override for patients.
- Concern was expressed that many pharmacists do not understand the 72 hour rule. Ideas were presented to educate providers about the 72 hour rule. Ideas for education include the Amber Sheet, Fax Blast, and a possible soft message on a rejection screen for drugs in the class.
- Julia Ozbolt stated that patients on these types of drugs should be under the close care of a specialist physician, so the 72 hour override would not be a serious issue
- Robyn Seely stated that there have not been any reported cases of patients not getting the Xa inhibitor medication because of a PA on existing Xa inhibitors with clinical criteria.
- **Lisa Hunt made a motion that all Xa inhibitors be included on the PDL, but not necessarily all be preferred. Elizabeth Young seconded the motion. All were in favor.**

2. Public Comment

- Lori Blackner PharmD. (Pfizer) – Said that in her experience as a retail pharmacist, there are risks of increases in stroke if patients are not compliant in taking their medications, especially Xa inhibitors.

- Bryan Larson (UofU) – Clarified the differences between the DUR board and the P&T committee.
3. Drug Utilization Review (DUR) Board update: Robyn Seely stated that the DUR board discussed anti-convulsant drugs in their past meeting.
 4. Due to time constraints a motion was made by Lisa Hunt to table the discussion of sulfonylurea class until next meeting. Kort Delost seconded the motion. All were in favor.
 5. Jameson Rice made a motion to close the meeting, Julia Ozbolt seconded the motion, all approved.
 6. Meeting adjourned.

Next Meeting Set for Thursday, August 15, 2013 - Sulfonylurea drug class

Minutes prepared by Trevor Smith

Recording available upon request, send email to medicaidpharmacy@utah.gov